Annual SG&A
$133.71 M
+$76.63 M+134.23%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual selling, general & administrative expenses is currently $133.71 million, with the most recent change of +$76.63 million (+134.23%) on 31 December 2023. During the last 3 years, it has risen by +$89.48 million (+202.28%). CPRX annual SG&A is now at all-time high.CPRX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$45.88 M
+$5.15 M+12.64%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly selling, general & administrative expenses is currently $45.88 million, with the most recent change of +$5.15 million (+12.64%) on 30 September 2024. Over the past year, it has increased by +$12.32 million (+36.71%). CPRX quarterly SG&A is now -2.25% below its all-time high of $46.94 million, reached on 31 March 2024.CPRX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
$680.38 M
+$142.80 M+26.56%
30 September 2024
Summary:
Catalyst Pharmaceuticals TTM selling, general & administrative expenses is currently $680.38 million, with the most recent change of +$142.80 million (+26.56%) on 30 September 2024. Over the past year, it has increased by +$574.62 million (+543.32%). CPRX TTM SG&A is now at all-time high.CPRX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +134.2% | +36.7% | +543.3% |
| 3 y3 years | +202.3% | +277.5% | +1267.5% |
| 5 y5 years | +742.2% | +468.7% | +2000.1% |
CPRX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +202.3% | -2.3% | +277.5% | at high | +499.3% |
| 5 y | 5 years | at high | +742.2% | -2.3% | +468.7% | at high | +211.8% |
| alltime | all time | at high | >+9999.0% | -2.3% | >+9999.0% | at high | +210.1% |
Catalyst Pharmaceuticals Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $45.88 M(+12.6%) | $175.58 M(+7.5%) |
| June 2024 | - | $40.73 M(-13.2%) | $163.26 M(+8.2%) |
| Mar 2024 | - | $46.94 M(+11.7%) | $150.93 M(+12.9%) |
| Dec 2023 | $133.71 M(+134.2%) | $42.04 M(+25.3%) | $133.71 M(+26.4%) |
| Sept 2023 | - | $33.56 M(+18.2%) | $105.76 M(+23.2%) |
| June 2023 | - | $28.40 M(-4.4%) | $85.85 M(+22.0%) |
| Mar 2023 | - | $29.72 M(+110.9%) | $70.37 M(+23.3%) |
| Dec 2022 | $57.09 M(+15.0%) | $14.09 M(+3.2%) | $57.09 M(+1.5%) |
| Sept 2022 | - | $13.65 M(+5.7%) | $56.22 M(+2.7%) |
| June 2022 | - | $12.92 M(-21.4%) | $54.73 M(+2.6%) |
| Mar 2022 | - | $16.43 M(+24.2%) | $53.34 M(+7.5%) |
| Dec 2021 | $49.63 M(+12.2%) | $13.23 M(+8.8%) | $49.63 M(-0.3%) |
| Sept 2021 | - | $12.15 M(+5.4%) | $49.75 M(+4.6%) |
| June 2021 | - | $11.53 M(-9.3%) | $47.59 M(+1.5%) |
| Mar 2021 | - | $12.72 M(-4.8%) | $46.89 M(+6.0%) |
| Dec 2020 | $44.23 M(+19.9%) | $13.35 M(+33.7%) | $44.23 M(+4.6%) |
| Sept 2020 | - | $9.98 M(-7.8%) | $42.29 M(+4.7%) |
| June 2020 | - | $10.83 M(+7.7%) | $40.37 M(+4.8%) |
| Mar 2020 | - | $10.06 M(-11.8%) | $38.53 M(+4.5%) |
| Dec 2019 | $36.88 M(+132.3%) | $11.41 M(+41.4%) | $36.88 M(+13.8%) |
| Sept 2019 | - | $8.07 M(-10.2%) | $32.40 M(+15.8%) |
| June 2019 | - | $8.99 M(+6.8%) | $27.97 M(+29.4%) |
| Mar 2019 | - | $8.42 M(+21.5%) | $21.62 M(+36.2%) |
| Dec 2018 | $15.88 M(+117.3%) | $6.93 M(+90.1%) | $15.88 M(+43.6%) |
| Sept 2018 | - | $3.64 M(+38.5%) | $11.06 M(+22.7%) |
| June 2018 | - | $2.63 M(-1.6%) | $9.01 M(+11.1%) |
| Mar 2018 | - | $2.67 M(+26.9%) | $8.11 M(+11.1%) |
| Dec 2017 | $7.30 M(-7.7%) | $2.11 M(+31.6%) | $7.30 M(+9.2%) |
| Sept 2017 | - | $1.60 M(-7.4%) | $6.69 M(+2.8%) |
| June 2017 | - | $1.73 M(-7.3%) | $6.51 M(-8.1%) |
| Mar 2017 | - | $1.87 M(+24.9%) | $7.08 M(-10.4%) |
| Dec 2016 | $7.91 M(-8.0%) | $1.49 M(+5.2%) | $7.91 M(-9.9%) |
| Sept 2016 | - | $1.42 M(-38.4%) | $8.78 M(-5.9%) |
| June 2016 | - | $2.31 M(-14.3%) | $9.33 M(-0.2%) |
| Mar 2016 | - | $2.69 M(+14.0%) | $9.35 M(+8.7%) |
| Dec 2015 | $8.60 M | $2.36 M(+19.5%) | $8.60 M(+9.7%) |
| Sept 2015 | - | $1.97 M(-14.9%) | $7.84 M(+10.6%) |
| June 2015 | - | $2.32 M(+19.4%) | $7.08 M(+25.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | $1.94 M(+21.4%) | $5.66 M(+26.4%) |
| Dec 2014 | $4.47 M(+102.0%) | $1.60 M(+30.8%) | $4.47 M(+27.4%) |
| Sept 2014 | - | $1.22 M(+37.2%) | $3.51 M(+28.6%) |
| June 2014 | - | $891.20 K(+17.3%) | $2.73 M(+15.7%) |
| Mar 2014 | - | $759.70 K(+18.9%) | $2.36 M(+6.6%) |
| Dec 2013 | $2.21 M(-13.5%) | $638.80 K(+44.7%) | $2.21 M(-5.2%) |
| Sept 2013 | - | $441.40 K(-15.4%) | $2.34 M(-7.4%) |
| June 2013 | - | $521.50 K(-14.9%) | $2.52 M(-0.5%) |
| Mar 2013 | - | $613.10 K(-19.4%) | $2.54 M(-0.9%) |
| Dec 2012 | $2.56 M(-5.1%) | $760.70 K(+21.0%) | $2.56 M(-10.9%) |
| Sept 2012 | - | $628.90 K(+17.6%) | $2.88 M(+4.1%) |
| June 2012 | - | $534.60 K(-16.1%) | $2.76 M(+1.6%) |
| Mar 2012 | - | $637.40 K(-40.7%) | $2.72 M(+0.8%) |
| Dec 2011 | $2.70 M(+22.3%) | $1.07 M(+107.8%) | $2.70 M(+18.6%) |
| Sept 2011 | - | $516.90 K(+5.1%) | $2.28 M(+5.0%) |
| June 2011 | - | $491.80 K(-20.1%) | $2.17 M(-2.0%) |
| Mar 2011 | - | $615.30 K(-5.6%) | $2.21 M(+0.2%) |
| Dec 2010 | $2.21 M(+1.3%) | $652.00 K(+59.6%) | $2.21 M(+1.4%) |
| Sept 2010 | - | $408.40 K(-23.7%) | $2.18 M(-1.5%) |
| June 2010 | - | $535.20 K(-12.4%) | $2.21 M(+0.2%) |
| Mar 2010 | - | $610.80 K(-1.8%) | $2.20 M(+1.2%) |
| Dec 2009 | $2.18 M(-0.3%) | $622.20 K(+41.0%) | $2.18 M(+5.0%) |
| Sept 2009 | - | $441.30 K(-16.8%) | $2.07 M(-1.0%) |
| June 2009 | - | $530.60 K(-9.1%) | $2.10 M(-1.5%) |
| Mar 2009 | - | $583.90 K(+12.5%) | $2.13 M(-2.6%) |
| Dec 2008 | $2.18 M(+7.2%) | $519.10 K(+12.1%) | $2.18 M(+4.7%) |
| Sept 2008 | - | $463.20 K(-17.5%) | $2.08 M(+0.8%) |
| June 2008 | - | $561.50 K(-12.2%) | $2.07 M(+6.6%) |
| Mar 2008 | - | $639.70 K(+52.1%) | $1.94 M(-4.7%) |
| Dec 2007 | $2.04 M(+6.4%) | $420.60 K(-5.9%) | $2.04 M(-6.6%) |
| Sept 2007 | - | $447.10 K(+3.0%) | $2.18 M(-23.2%) |
| June 2007 | - | $434.20 K(-40.9%) | $2.84 M(+13.9%) |
| Mar 2007 | - | $734.60 K(+30.2%) | $2.49 M(+41.8%) |
| Dec 2006 | $1.91 M(+289.1%) | $564.20 K(-49.0%) | $1.76 M(+47.3%) |
| Sept 2006 | - | $1.11 M(+1175.1%) | $1.19 M(+1275.1%) |
| June 2006 | - | $86.80 K | $86.80 K |
| Dec 2005 | $491.70 K(+198.5%) | - | - |
| Dec 2004 | $164.70 K | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual SG&A year-on-year change?
- What is Catalyst Pharmaceuticals quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly SG&A year-on-year change?
- What is Catalyst Pharmaceuticals TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM SG&A year-on-year change?
What is Catalyst Pharmaceuticals annual selling, general & administrative expenses?
The current annual SG&A of CPRX is $133.71 M
What is the all time high annual SG&A for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual selling, general & administrative expenses is $133.71 M
What is Catalyst Pharmaceuticals annual SG&A year-on-year change?
Over the past year, CPRX annual selling, general & administrative expenses has changed by +$76.63 M (+134.23%)
What is Catalyst Pharmaceuticals quarterly selling, general & administrative expenses?
The current quarterly SG&A of CPRX is $45.88 M
What is the all time high quarterly SG&A for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly selling, general & administrative expenses is $46.94 M
What is Catalyst Pharmaceuticals quarterly SG&A year-on-year change?
Over the past year, CPRX quarterly selling, general & administrative expenses has changed by +$12.32 M (+36.71%)
What is Catalyst Pharmaceuticals TTM selling, general & administrative expenses?
The current TTM SG&A of CPRX is $680.38 M
What is the all time high TTM SG&A for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM selling, general & administrative expenses is $175.58 M
What is Catalyst Pharmaceuticals TTM SG&A year-on-year change?
Over the past year, CPRX TTM selling, general & administrative expenses has changed by +$574.62 M (+543.32%)